{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"93.2","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"ORR:% of participants with best overall response; confirmed stringent complete response(sCR),CR, very good partial response(VGPR) or PR per International Myeloma Working Group criteria.sCR: CR\\& normal serum free light chain(sFLC)ratio \\&absence of clonal cells in BMB/BMA by immunohistochemistry, immunofluorescence or flow cytometry.CR: negative immunofixation on serum \\&urine, disappearance of soft tissue plasmacytoma \\&\\<5% plasma cells in BMA, if disease measured by sFLC only,preceding criteria plus normal sFLC ratio.VGPR:Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum\\&urine M-protein level \\<100mg/24h.PR:\\>=50% reduction in serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h. If serum \\& urine M-protein unmeasurable,VGPR \\& PR: \\>=90% \\&\\>=50% decrease in difference respectively between involved \\& uninvolved sFLC levels \\& if present at baseline,\\>=90% \\& \\>=50% reduction in soft tissue plasmacytomas' size.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"NUMBER","populationDescription":"SAS included all enrolled participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (maximum of 65.1 weeks of treatment)","title":"Objective Response Rate (ORR): Percentage of Participants With Objective Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}